ESTRO 2024 - Abstract Book

S1682

Clinical - Lung

ESTRO 2024

Conclusion:

High rates of severe late ET were observed in patients with LA-NSCLC treated with personalised, hypofractionated dose-escalation in the PET- Boost trial. The multivariable model that best predicted G≥3 oesophageal toxicity included higher D2 oesophagus dose and chemotherapy regime, where compared to no/seq chemotherapy, cCT doublet was strongly associated.

Keywords: dose-escalation, toxicity, esophagus

1602

Digital Poster

PREHABS: Reducing inequalities in dietetic provision in the radical lung radiotherapy pathway.

Gillian F Williams 1,2 , Janine C Bestall 3 , Shaunna Burke 4 , Carole Burnett 2,5 , Samuel Greenwood-Wilson 2,5 , Emma Morgan 2,5 , Rachael L Murray 6 , Kevin N Franks 2,7 1 Leeds Teaching Hospitals NHS Trust, Department of Nutrition and Dietetics, Leeds, United Kingdom. 2 Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, United Kingdom. 3 University of Leeds, Leeds Institute of Health Sciences, Leeds, United Kingdom. 4 University of Leeds, School of Biomedical Sciences, Leeds, United Kingdom. 5 University of Leeds, Leeds Institute of Medical Research at St James’s Hospital, Leeds, United Kingdom. 6 University of Nottingham, Academic Unit of Lifespan and Population Health, School of Medicine, Nottingham, United Kingdom. 7 University of Leeds, Faculty of Medicine and Health, Leeds, United Kingdom